ImmunoMet creates anti-cancer metabolic therapy: Complete $5 million Series B financing
Recently, ImmunoMet Therapeutics from Houston, USA announced the completion of a $5 million Series B round of financing. This round of funding was funded by Dr. Sung-wuk Kim, CEO of Intervest, SL Investment, NHN Investment, Mirae Asset Venture Investments, GNTech and ImmunoMet. Founded in July 2015, ImmunoMet Therapeutics is a biotech start-up company that develops new anticancer drugs and cancer immunotherapies using cell metabolism. ImmunoMet was formed by splitting from the Korean pharmaceutical company HanAll Biopharma, and the former CEO of HanAll Biopharma, Dr. Sung-wuk Kim, served as the president and CEO of the new company. (ImmunoMet product pipeline, picture source: company official website) ImmunoMet inhibits cancer by modulating the major metabolic signals of cancer cells and immune cells, and promotes the growth of anti-cancer immune cells. The company currently has four candidate drugs in progress, of which the fastest-growing IM156 is an OXPHOS inhibitor, currently in pre-clinical development, and is expected to enter Phase 1 clinical trials in the second quarter of this year. The drug showed good results in the treatment of brain tumors and lung cancer in preclinical trials. In addition, the company's cancer immune product, IM188, is currently being developed in combination with other immunotherapies, including anti-PD1 therapy, which is in the late stage of lead optimization and has shown a tumor regression effect on kidney cancer. It is reported that this round of newly-funded funds will be mainly used in the Phase I clinical trial of IM156. Tetanus Toxoid Vaccine,Toxoid Vaccine,Hep B Immune Globulin,Immunoglobulin Injections FOSHAN PHARMA CO., LTD. , https://www.full-pharma.com
